Wells Fargo & Company Adc Therapeutics Sa Transaction History
Wells Fargo & Company
- $433 Billion
- Q4 2024
A detailed history of Wells Fargo & Company transactions in Adc Therapeutics Sa stock. As of the latest transaction made, Wells Fargo & Company holds 41,832 shares of ADCT stock, worth $74,042. This represents 0.0% of its overall portfolio holdings.
Number of Shares
41,832
Previous 29,998
39.45%
Holding current value
$74,042
Previous $94,000
11.7%
% of portfolio
0.0%
Previous 0.0%
Shares
7 transactions
Others Institutions Holding ADCT
# of Institutions
85Shares Held
55.3MCall Options Held
24.1KPut Options Held
44.7K-
Redmile Group, LLC San Francisco, CA15.7MShares$27.7 Million2.44% of portfolio
-
Prosight Management, LP Dallas, TX9.52MShares$16.8 Million5.62% of portfolio
-
Orbimed Advisors LLC San Diego, CA5.97MShares$10.6 Million0.32% of portfolio
-
Morgan Stanley New York, NY3.96MShares$7 Million0.0% of portfolio
-
Black Rock Inc. New York, NY3.55MShares$6.29 Million0.0% of portfolio
About ADC Therapeutics SA
- Ticker ADCT
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 77,645,296
- Market Cap $137M
- Description
- ADC Therapeutics SA, a commercial-stage biotechnology company, develops antibody drug conjugates (ADC) for patients suffering from hematological malignancies and solid tumors. Its flagship product ZYNLONTA that is in Phase II clinical trial for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma;...